Ptc Therapeutics (PTCT) EBT Margin (2016 - 2025)
Historic EBT Margin for Ptc Therapeutics (PTCT) over the last 14 years, with Q3 2025 value amounting to 10.94%.
- Ptc Therapeutics' EBT Margin rose 388600.0% to 10.94% in Q3 2025 from the same period last year, while for Sep 2025 it was 28.4%, marking a year-over-year increase of 1004100.0%. This contributed to the annual value of 74.22% for FY2024, which is 94600.0% up from last year.
- Ptc Therapeutics' EBT Margin amounted to 10.94% in Q3 2025, which was up 388600.0% from 39.72% recorded in Q2 2025.
- In the past 5 years, Ptc Therapeutics' EBT Margin ranged from a high of 79.06% in Q1 2025 and a low of 154.99% during Q4 2024
- For the 5-year period, Ptc Therapeutics' EBT Margin averaged around 71.64%, with its median value being 82.92% (2021).
- In the last 5 years, Ptc Therapeutics' EBT Margin soared by 1399900bps in 2021 and then crashed by -749700bps in 2024.
- Ptc Therapeutics' EBT Margin (Quarter) stood at 83.89% in 2021, then crashed by -38bps to 115.48% in 2022, then skyrocketed by 31bps to 80.01% in 2023, then crashed by -94bps to 154.99% in 2024, then soared by 93bps to 10.94% in 2025.
- Its EBT Margin was 10.94% in Q3 2025, compared to 39.72% in Q2 2025 and 79.06% in Q1 2025.